应用实用短程放疗方案减轻局部晚期乳腺癌的疾病负担:HYPORT姑息研究结果
HYPORT和HYPORT B两项1/2期研究评估大分割姑息性乳腺放疗的安全性及疗效,58例患者分别接受35 Gy/10次或26 Gy乳腺/32 Gy肿瘤加量/5次方案。未报告3级毒性,3个月时溃疡、出血、蕈样病变及分泌物等症状改善,代谢缓解率分别为90%和83%,生活质量改善,1年内仅10%患者局部复发。作者认为该方案可考虑作为局部区域症状控制的标准。
要点
- HYPORT方案35 Gy/10次和HYPORT B方案26 Gy乳腺/32 Gy肿瘤加量/5次均未报告3级毒性。
- 3个月时HYPORT研究溃疡从58%降至22%(P=.013),出血从22%降至0%(P=.074)。
- HYPORT B研究蕈样病变从26%降至0%(P=.041),分泌物从57%降至8.7%(P=.003)。
核心结论
- 姑息性超大分割乳腺放疗耐受性良好、有效,可产生持久缓解并改善生活质量。
- 作者认为该方案可考虑作为局部区域症状控制的标准。
研究设计与样本
- HYPORT和HYPORT B两项1/2期研究,分别采用35 Gy/10次和26 Gy乳腺/32 Gy肿瘤加量/5次方案,总治疗时间从10天缩短至5天。
- 共58例患者完成治疗,多数既往接受过全身治疗。
主要发现
- 未报告3级毒性。
- HYPORT研究3个月时溃疡从58%降至22%(P=.013),出血从22%降至0%(P=.074)。
- HYPORT B研究3个月时溃疡从64%降至39%(P=.2),蕈样病变从26%降至0%(P=.041),出血从26%降至4.3%(P=.074),分泌物从57%降至8.7%(P=.003)。
- 两项研究代谢缓解率分别为90%和83%,生活质量评分均有改善,1年内仅10%患者局部复发。
临床怎么用
- 作者认为姑息性超大分割乳腺放疗可考虑作为局部区域症状控制的标准。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Locally advanced breast cancers lead to debilitating local symptoms. Treatment of these women encountered commonly in less resourced countries is not backed by strong evidence. We formulated the HYPORT and HYPORT B phase 1/2 studies to evaluate the safety and efficacy of hypofractionated palliative breast radiation therapy. METHODS AND MATERIALS: Two studies (35 Gy/10 fractions; HYPORT ) and (26 Gy to breast/32 Gy tumor boost in 5 fractions; HYPORT B) were designed with increasing hypofractionation to save overall treatment time from 10 to 5 days. We report the acute toxicity, symptomatic, metabolic response, and quality of life (QOL) changes after radiation therapy. RESULTS: Fifty-eight patients, the majority of whom were pretreated with systemic therapy, completed the treatment. No grade 3 toxicity was reported. Response assessment at 3 months showed improvement in ulceration (58% vs 22%, P = .013) and bleeding (22% vs 0%, P = .074) within the HYPORT study. Similarly, in the HYPORT B study, ulceration (64% and 39%, P = .2), fungating (26% and 0%, P = .041), bleeding (26% and 4.3%, P = .074), and discharge (57% and 8.7%, P = .003) was reduced. Metabolic response was noted in 90% and 83% of patients, respectively, in the 2 studies. Improvement in the QOL scores were evident in both studies. Only 10% of the patients relapsed locally within 1 year. CONCLUSIONS: Palliative ultrahypofractionated radiation therapy to the breast is well tolerated, is effective, and results in a durable response with improved QOL. This could be considered a standard for locoregional symptom control.
引用
- Chatterjee S, Chakrabarty S, Santosham R, et al. Alleviating Morbidity From Locally Advanced Breast Cancer Using a Practical and Short Radiation Therapy Regimen: Results of the HYPORT Palliative Studies. Int J Radiat Oncol Biol Phys. 2023. PMID: 36868522. doi:10.1016/j.ijrobp.2023.02.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。